# Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

> **NCT00642421** · PHASE3 · TERMINATED · sponsor: **Ambrilia Biopharma, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** C2L-OCT-01 PR, 10 or 20 mg
- **DRUG:** C2L-OCT-01 PR, 20 mg

## Key facts

- **NCT ID:** NCT00642421
- **Lead sponsor:** Ambrilia Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 40 (ESTIMATED)
- **Why stopped:** Commercial reasons
- **Last updated:** 2010-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00642421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00642421, "Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00642421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*